Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 9;8(2):e000706. doi: 10.1136/jitc-2020-000706

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Tumor cells predominate in the adherent cell population within clear cell renal cell carcinoma (ccRCC) and express immunosuppressive ligands. (A) H&E staining of adjacent normal renal cortex and autologous ccRCC (top panel) and corresponding passage 0 adherent cell lines established from those tissues (bottom panel). (B) Pan-cytokeratin (PanCK) and PAX-8 staining of RCC tissue (top panel) and the autologous, adherent cells at passage 0 derived from the same sample (bottom panel). (C) PD-L1 expression on the surface of adherent primary RCC cells cultured in fresh media (FM) or conditioned media from autologous TILs (TIL CM). (D) Galectin-9 (Gal-9) expression within adherent primary RCC cells. (E) Human leukocyte antigen G (HLA-G) expression on adherent primary RCC cells. (F) 40× photomicrographs of TILs expanding in 24-well plates using the panning, Pre-Rapid Expansion Protocol (PreREP), and fresh tumor digest (FTD)+ beads protocols at 18 hours, day 4, and day 6 post-surgery. PE, phycoerythrin; PD-L1, programmed cell death ligand-1.